Rafferty Asset Management, LLC Cassava Sciences Inc Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

A detailed history of Rafferty Asset Management, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 12,487 shares of SAVA stock, worth $49,698. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,487

Previous 11,257 10.93%

Holding current value

$49,698

Previous $139,000 164.03%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$9.57 - $35.08 $11,771 - $43,148	1,230 Added 10.93%	12,487 $367,000
Q2 2024 Aug 13, 2024	BUY	$12.35 - $26.11 $15,894 - $33,603	1,287 Added 12.91%	11,257 $139,000
Q1 2024 May 13, 2024	BUY	$18.44 - $26.41 $183,846 - $263,307	9,970 New	9,970 $202,000
Q1 2023 May 11, 2023	BUY	$23.46 - $36.44 $35,635 - $55,352	1,519 Added 19.86%	9,167 $221,000
Q4 2022 Feb 13, 2023	BUY	$27.82 - $44.16 $4,534 - $7,198	163 Added 2.18%	7,648 $225,000
Q3 2022 Nov 14, 2022	SELL	$16.33 - $51.06 $18,583 - $58,106	-1,138 Reduced 13.2%	7,485 $313,000
Q2 2022 Aug 12, 2022	SELL	$17.22 - $38.47 $60,924 - $136,106	-3,538 Reduced 29.09%	8,623 $242,000
Q1 2022 May 13, 2022	SELL	$32.6 - $53.05 $243,880 - $396,867	-7,481 Reduced 38.09%	12,161 $452,000
Q4 2021 Feb 10, 2022	BUY	$36.77 - $90.91 $165,759 - $409,822	4,508 Added 29.79%	19,642 $858,000
Q3 2021 Nov 10, 2021	BUY	$41.79 - $135.3 $359,226 - $1.16 Million	8,596 Added 131.48%	15,134 $940,000
Q2 2021 Aug 10, 2021	BUY	$32.15 - $89.72 $210,196 - $586,589	6,538 New	6,538 $559,000

Others Institutions Holding SAVA

# of Institutions

207

Shares Held

14M

Call Options Held

2.98M

Put Options Held

6.57M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $160M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Cassava Sciences Inc Transaction History